Immunotherapies targeting immune checkpoint proteins like cytotoxic T lymphocyte‐associated‐antigen 4 (CTLA4) and programmed death‐1/ligand‐1(PD‐1/PD‐L1) have shown promise in various cancers but have only shown partial effectiveness in EC with specific molecular features [7]. Here, PDCD1 is linked to cancer.